Drug Farm获得5600万美元的融资，用于将B型铅肝药物推进临床试

StephenW

Drug Farm Closes $56M USD Financing for Advancement of Lead Hepatitis B Drug into Clinical Trials

Published: Feb 09, 2021
Logo
Feb. 9, 2021 10:00 UTC

SHANGHAI & GUILFORD, Conn.--(BUSINESS WIRE)-- Drug Farm, a China- and US-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has completed financing totaling $56 million USD. This funding will enable the Company to initiate human clinical trials with its lead drug DF-006, a first-in-class, orally bioavailable drug for hepatitis B virus (HBV) infection and other liver diseases. The financing will also be used to further advance Drug Farm’s additional pipeline candidates for therapies in cancer and autoimmune diseases. Drug Farm investors include BioVeda China Fund (BVCF), WuXi AppTec’s corporate venture fund, South China Venture Capital (SCVC), Detong Capital, and Zhejiang United Investment Group (ZUIG).

“Since the inception of Drug Farm, we have successfully leveraged our forward genetics technology, piggyBac transposon mutagenesis to discover new targets, connect them to diseases, and advance candidates toward clinical development,” said Dr. Tian Xu, founder and Chairman of Drug Farm. “Using our deep learning AI technology, we have been able to rapidly develop small molecule drugs against these targets, with an initial focus on HBV.”

Dr. Henri Lichenstein, CEO and Board Member of Drug Farm, commented, “HBV infection remains being a big unmet medical need worldwide. Despite the availability of several drugs that can decrease viral load, cure is seldom achieved. DF-006 is a new drug to treat HBV; we appreciate the commitment and confidence of Drug Farm’s investors for the financing enabling us to advance our candidate into clinical trials.”

“Treatments aiming to obtain HBsAg and/or HBV cccDNA clearance will represent a real breakthrough in HBV therapy,” said Dr. Lishan Su, Drug Farm Scientific Advisory Board member and Director of Division of Virology, Pathogenesis, and Cancer of the Institute of Human Virology at the University of Maryland School of Medicine. “DF-006 represents an exciting new mechanistic approach to treat chronic HBV through modulation of the body’s own innate immunity.”

About Drug Farm

Drug Farm is a China- and US-based biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. For more information please visit: www.drug-farm.com/

StephenW

Drug Farm获得5600万美元的融资，用于将B型铅肝药物推进临床试验

发布时间：2021年2月9日
商标
2021年2月9日10:00 UTC

位于美国和美国的生物技术公司Drug Farm利用遗传和人工智能技术发现和开发创新的免疫调节疗法，目前已完成总融资5600万美元。这笔资金将使该公司能够使用其领先的药物DF-006进行人体临床试验，该药物是用于治疗乙型肝炎病毒（HBV）感染和其他肝病的一流的口服生物利用药物。这笔资金还将用于进一步推进药物农场针对癌症和自身免疫性疾病的疗法的其他候选药物。药物农场的投资者包括BioVeda中国基金（BVCF），药明康德公司的企业风险基金，华南风险投资（SCVC），德通资本和浙江联合投资集团（ZUIG）。

“自药物农场成立以来，我们已成功利用我们的先进遗传技术，piggyBac转座子诱变来发现新的靶标，将其与疾病联系起来，并推动候选者进入临床发展，”药物农场创始人兼董事长田旭博士说： 。 “使用我们的深度学习AI技术，我们能够针对这些目标快速开发小分子药物，最初的重点是HBV。”

药物农场首席执行官兼董事会成员Henri Lichenstein博士评论说：“ HBV感染仍然是全球范围内尚未满足的一大医疗需求。尽管有几种药物可以降低病毒载量，但很少能治愈。 DF-006是治疗乙肝的新药。我们非常感谢Drug Farm的投资人的承诺和信心，这笔资金使我们能够将候选人推进临床试验。”

“旨在获得HBsAg和/或HBV cccDNA清除率的治疗将代表HBV治疗的真正突破，”人类医学研究所病毒农场科学顾问委员会成员兼病毒学，发病机制和癌症部主任Su Lishan Su博士说。马里兰大学医学院病毒学。 “ DF-006代表了一种通过调节人体自身的先天免疫力来治疗慢性HBV的令人兴奋的新机制。”

关于药物农场

Drug Farm是一家基于中国和美国的生物技术公司，致力于开发针对HBV，癌症和自身免疫性疾病的先天免疫的创新疗法。 Drug Farm独特的IDInVivo平台结合了遗传学和AI方面的突破性技术来发现新疗法。 IDInVivo技术可以直接评估具有完整免疫系统的活体动物的基因靶标。通过使用IDInVivo平台，药物农场（Drug Farm）已经确定了新颖的先天免疫途径和靶标，并且正在迅速将多个一流的候选药物推进临床开发。欲了解更多信息，请访问：www.drug-farm.com/